FAST at ASGCT 2026
FAST leadership takes the stage at ASGCT’s Annual Meeting, driving key conversations on gene therapy, clinical collaboration, and patient advocacy shaping Angelman syndrome research.
Career Development Awards Expand the Next Wave of Angelman Syndrome Research
FAST and ASGCT are funding three Career Development Awards for early-career scientists, advancing gene editing, siRNA, and delivery approaches to restore UBE3A in Angelman syndrome.
Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career Scientists
FAST partners with ASGCT to fund up to three $100,000 Career Development Awards, recruiting early-career scientists to advance neuron-targeted gene and cell therapies for Angelman syndrome.”
More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025
FAST attended this year’s ASGCT conference, where Angelman syndrome was featured in 10 scientific presentations and multiple talks—proof the community is helping drive the future of gene and cell therapy.